OPERATING RESPONSIBLY
ENVIRONMENTAL, SOCIAL & GOVERNANCE (ESG)
ESG is critical to achieving our core objectives and delivering value to our patients, communities, employees, partners and shareholders, and involves the full commitment from Celadon’s executive team.
UK domestic production: The UK market is currently reliant on imports from overseas. By investing in production at our state of the art UK facility, we are reducing the sector’s carbon footprint through reduced freight, logistics and transport.
Indoor cultivation optimising yields: Our indoor hydroponic growing system produces a higher yield, less wastage and more careful management of water when compared to outdoor and greenhouse cultivation methods.
Clean energy consumption: While cultivation is energy-intensive today, the business invested in early 2023 to supply its UK facility fully from renewable energy and is currently exploring on-site renewable energy generation options.
There are currently over 20m chronic pain suffers in the UK. Celadon’s purpose is to improve the quality of life for patients most in need in society through alternative cannabis-based treatments.
With 1.4m UK patients currently using the black market for cannabis for medicinal purposes, Celadon provides a safe, regulated and value for money alternative cannabis treatment.
Our MHRA conditionally approved medical cannabis trial outcome aims for reimbursement
from the NHS to increase access
to treatment
for patients across society.
Celadon is a responsible employer, investing in the development and wellbeing of our people. With comprehensive benefits, an employee share scheme, and our dedicated apprenticeship programme we take employee engagement and retention seriously.
Our treatments aim to become an alternative to opioid based drugs with adverse side effects including addition and overdoses, currently used to treat chronic pain.
We operate a flat management structure with an inclusive and collaborative ethos underpinned by respect, trust and integrity as core values we hold ourselves accountable to when working with our colleagues, customers, suppliers and partners.
Corporate Governance: Celadon is listed on the AIM market of the London Stock Exchange and compliant with the QCA Corporate Governance Code.
Board of Directors: The executive team comprises of seven highly experienced and diverse plc directors, four of whom are independent non-executive directors responsible for the oversight of strategy, operations, financial accounts and risk
management systems.
ENVIRONMENTAL
UK domestic production: The UK market is currently reliant on imports from overseas. By
investing in production at our state of the art UK facility, we are reducing the sector’s
carbon footprint through reduced freight, logistics and transport.
Indoor cultivation optimising yields: Our indoor hydroponic growing system, produces a
higher yield, less wastage and more careful management of water when compared to
outdoor and greenhouse cultivation methods.
Reducing energy consumption: While cultivation is energy-intensive today, our
investment in new technologies and innovation including ultra-efficient LED lighting and
off-peak growing, alongside constant reviews of renewable energy options, is optimising
our production methods and reducing energy consumption
SOCIAL
QUALITY OF LIFE
There are currently over 20m chronic pain suffers in the UK. Celadon’s purpose is to improve the quality of life for patients most in need in society through alternative cannabis-based treatments.
IMPROVING ACCESS
Our MHRA conditionally approved medical cannabis trial outcome aims for reimbursement from the NHS to increase access to treatment for patients across society.
REDUCED HARM
Our treatments aim to become an alternative to opioid based drugs with adverse side effects including addition and overdoses, currently used to treat chronic pain.
A SAFER OPTION
With 1.4m UK patients currently using the black market for cannabis for medicinal purposes, Celadon provides a safe, regulated and value for money alternative cannabis treatment.
INVESTMENT IN OUR PEOPLE
Celadon is a responsible employer, investing in the development and wellbeing of our people. With comprehensive benefits, an employee share scheme, and our dedicated apprenticeship programme we take employee engagement and retention seriously.
OPEN CULTURE
We operate a flat management structure with an inclusive and collaborative ethos underpinned by respect, trust and integrity as core values we hold ourselves accountable to when working with our colleagues, customers, suppliers and partners.
GOVERNANCE
Corporate Governance: Celadon is listed on the AIM market of the London Stock Exchange and compliant with the QCA Corporate Governance Code.
Board of Directors: The executive team comprises of seven highly experienced and diverse plc directors, four of whom are independent non-executive directors responsible for the oversight of strategy, operations, financial accounts and risk
management systems.
As a UK Pharmaceutical company aiming to develop medicines that might be re-imbursed on the UK’s National Health Service (NHS), Celadon will work to align with the NHS’s requirement that by 2027 suppliers report emissions and publish a carbon reduction plan aligned with its 2045 net zero targets.
